Sanofi, a leading French pharmaceutical company, plans to invest approximately €1 billion (about $1.1 billion) to establish a new insulin production facility in Beijing. This marks Sanofi's largest single investment in China and is part of a broader strategy to expand its production capacity in Asia. The new facility will be Sanofi's fourth in China and its second in Beijing, focusing on meeting the medication needs of local diabetes patients.
As one of the world's largest insulin producers, Sanofi is tapping into the significant potential of the Chinese diabetes treatment market. As of 2021, around 140 million adults in mainland China were diagnosed with diabetes, with a prevalence rate nearing 12%. This investment aligns with the Chinese government's efforts to attract foreign companies to expand their local operations. Global pharmaceutical giants like AstraZeneca and Roche are also adopting a "In China, For China" strategy to cater to the growing Chinese healthcare market.
